Trial · NCT01954628
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Primary Efficacy Variable Was the AAC for Daily EXACT Scores During the 12-week Treatment Period. | AQX-1125 (200mg) | 415.4 | 95% Confidence Interval 290.7 to 540.1 | Area Above Curve on Daily Exact Score | |
| The Primary Efficacy Variable Was the AAC for Daily EXACT Scores During the 12-week Treatment Period. | Placebo | 391.7 | 95% Confidence Interval 268.2 to 515.1 | Area Above Curve on Daily Exact Score | |
| Change From Baseline in COPD Assessment Tool (CAT) Score | AQX-1125 (200 mg) | -4.05 | 95% Confidence Interval -5.06 to -3.04 | COPD Assessment Tool Score | |
| Change From Baseline in COPD Assessment Tool (CAT) Score | Placebo | -3.71 | 95% Confidence Interval -4.71 to -2.71 | COPD Assessment Tool Score | |
| Analysis of the Number of COPD Exacerbations (Medically Treated Event (MTE)) | AQX-1125 (200 mg) | 1.776 | 95% Confidence Interval 1.374 to 2.297 | Number of exacerbations/year | |
| Analysis of the Number of COPD Exacerbations (Medically Treated Event (MTE)) | Placebo | 1.641 | 95% Confidence Interval 1.261 to 2.135 | Number of exacerbations/year | |
| Time to First COPD Exacerbation | AQX-1125 (200 mg) | 38.1 | Standard Deviation 21.3 | day(s) | |
| Time to First COPD Exacerbation | Placebo | 43.9 | Standard Deviation 24.1 | day(s) | |
| The Number of Subjects With at Least One COPD Exacerbation. | AQX-1125 (200 mg) | 48 | participants | ||
| The Number of Subjects With at Least One COPD Exacerbation. | Placebo | 51 | participants | ||
| Change From Baseline in FEV1 | AQX-1125 (200mg) | -0.02 | 95% Confidence Interval -0.06 to 0.02 | Liter | |
| Change From Baseline in FEV1 | Placebo | 0.01 | 95% Confidence Interval -0.03 to 0.06 | Liter | |
| AQX-1125 Concentrations in Plasma (Trough Values) | AQX-1125 Week 2 | 170.1 | Geometric Coefficient of Variation 70.5 | micrograms per Liter | |
| AQX-1125 Concentrations in Plasma (Trough Values) | AQX-1125 Week 4 | 163.9 | Geometric Coefficient of Variation 74.5 | micrograms per Liter | |
| AQX-1125 Concentrations in Plasma (Trough Values) | AQX-1125 Week 12 | 120.5 | Geometric Coefficient of Variation 80.0 | micrograms per Liter |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01954628/results